Feb 4th, 2026
Novo CEO Says Volumes to Compensate for Price Decreases
Novo Nordisk Chief Executive Officer Mike Doustdar talks about the company's outlook as it faces headwinds on its main obesity and diabetes drugs and its shares plunged. Doustdar tells Bloomberg Television he is "confident" that "the volume build up will happen." He also talks about job cuts and says "we don't have any plans of mass layoffs."
